Trial Profile

Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UCART 123 (Primary) ; Alemtuzumab; Cyclophosphamides; Fludarabine; Tocilizumab
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Acronyms AMELI-01
Sponsors Cellectis

07 Aug 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
07 Aug 2025 Status changed from recruiting to active, no longer recruiting.
04 Nov 2024 According to a Cellectis media release, the Company decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com